Bayer to buy Perfuse Therapeutics in up to $2.45 billion deal

Bayer said on Wednesday that it will buy biopharmaceutical company Perfuse Therapeutics to ‌complement ⁠its ⁠ophthalmology pipeline.

The deal ​has a potential value of ​up to $2.45 billion, the company said in a ​statement, with ⁠a $300 million ‌upfront ​payment and ​additional development, regulatory ⁠and commercial milestone payments based on ​success criteria.

The deal will give Bayer full rights to PER-001, a small molecule endothelin receptor ‌antagonist (ERA) in phase II clinical development, for the treatment of ⁠glaucoma and diabetic retinopathy.


The acquisition will become effective after receiving the necessary antitrust clearances and Perfuse stockholder approvals, Bayer said.